A breakthrough treatment for debilitating Women’s Health conditions
get in touch
KaNDy Therapeutics Limited is a company incorporated under the laws of England and Wales and having its registered offices at Stevenage Bioscience Catalyst, Incubator Building, Gunnels Wood Road, Stevenage, HERTS, SG1 2FX, UK (company no. 10753028).
Launched in 2017, KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of its unique NK-1,3 receptor antagonist NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions.